actinium pharmaceuticals, inc. (www.actiniumpharma.com) (nyse mkt: atnm) is a new york-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. the company’s lead radiopharmaceutical iomab™-b will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. the company is preparing a single, pivotal, multicenter phase 3 clinical study of iomab™-b in refractory and relapsed acute myeloid leukemia (aml) patients over the age of 55 with a primary endpoint of durable complete remission. the company’s second program, actimab-a, is continuing its clinical development in a phase 1/2 trial for newly diagnosed aml patients o
Company profile
Ticker
ATNM
Exchange
Website
CEO
Sandesh Seth
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cactus Ventures, Inc.
SEC CIK
Corporate docs
IRS number
880378336
ATNM stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
26 Apr 24
S-8
Registration of securities for employees
29 Mar 24
10-K
2023 FY
Annual report
29 Mar 24
EFFECT
Notice of effectiveness
6 Feb 24
S-3/A
Shelf registration (amended)
2 Feb 24
CORRESP
Correspondence with SEC
2 Feb 24
8-K
Departure of Directors or Certain Officers
1 Dec 23
ARS
2022 FY
Annual report to shareholders
9 Nov 23
DEF 14A
Definitive proxy
9 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
Latest ownership filings
SC 13G/A
Bigger Capital, LLC
9 Feb 24
SC 13G
BlackRock Inc.
29 Jan 24
4
C. David Nicholson,
29 Dec 23
4
Richard I Steinhart
29 Dec 23
4
Steve O'Loughlin
29 Dec 23
4
Ajit Shetty
29 Dec 23
4
SANDESH SETH
29 Dec 23
4
Jeffrey W. Chell
29 Dec 23
SC 13G/A
BIGGER CAPITAL FUND L P
6 Feb 23
4
SANDESH SETH
19 Aug 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 83.29 mm | 83.29 mm | 83.29 mm | 83.29 mm | 83.29 mm | 83.29 mm |
Cash burn (monthly) | 2.77 mm | 2.44 mm | 4.78 mm | 4.41 mm | 3.71 mm | 3.97 mm |
Cash used (since last report) | 19.10 mm | 16.82 mm | 33.05 mm | 30.44 mm | 25.62 mm | 27.42 mm |
Cash remaining | 64.19 mm | 66.47 mm | 50.24 mm | 52.85 mm | 57.67 mm | 55.87 mm |
Runway (months of cash) | 23.2 | 27.3 | 10.5 | 12.0 | 15.6 | 14.1 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Dec 23 | Jeffrey W. Chell | Stock Option Common Stock | Grant | Acquire A | No | No | 5 | 70,311 | 351.56 k | 70,311 |
28 Dec 23 | Sandesh Seth | Stock Option Common Stock | Grant | Acquire A | No | No | 5 | 984,367 | 4.92 mm | 984,367 |
28 Dec 23 | Shetty Ajit | Stock Option Common Stock | Grant | Acquire A | No | No | 5 | 70,311 | 351.56 k | 70,311 |
28 Dec 23 | Steve O'Loughlin | Stock Option Common Stock | Grant | Acquire A | No | No | 5 | 253,123 | 1.27 mm | 253,123 |
28 Dec 23 | Richard I Steinhart | Stock Option Common Stock | Grant | Acquire A | No | No | 5 | 70,311 | 351.56 k | 70,311 |
News
Actinium Highlights Ability Of Iomab-B To Overcome High-Risk TP53 Mutation Resulting In Improvement In Overall Survival In Patients With Active Relapsed Refractory AML At The European Bone Marrow Transplant Annual Meeting
18 Apr 24
HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $50 Price Target
1 Apr 24
HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $50 Price Target
26 Mar 24
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
26 Mar 24
Maxim Group Maintains Buy on Actinium Pharma, Raises Price Target to $30
19 Mar 24
Press releases
Investment Opportunities in Biotech Amidst Federal Rate Uncertainties (ATNM)
22 Apr 24
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
19 Apr 24
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
18 Apr 24
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
18 Apr 24
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest
17 Apr 24